> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-32/
- Published: 2020-08-04T12:00:00.000Z
- Updated: 2026-09-14T16:23:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147355

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**Acrx Specialty Pharmacy**, Las Vegas, NV (7/24): FDA inspected the firm in March and found multiple violations of drug compounding and other provisions of the Federal Food, Drug, and Cosmetic Act in the production of finished drugs. For example, Acrx failed to meet requirements for compounding human drug products, including failing to have valid prescriptions for individually identified patients for some of its drugs. It also produced adulterated drug products intended or expected to be sterile that instead were prepared, packed, or held under insanitary conditions. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/acrx-specialty-pharmacy-inc-609518-07242020?ref=fdaweb.com).

**Fishman Chemical**, Vero Beach, FL (7/21): A recent review by FDA finds that a Web site operated by the company sells 11 unapproved new animal drugs. The agency also determined that Fishman is continuing to sell chloroquine phosphate, an adulterated new animal drug, for which it received a 4/15 Warning Letter. “To date, FDA has not received the requested response to this Warning Letter describing your proposed corrective actions for this violation, nor have you responded to our voicemail of 4/20,” the letter says. Fishman was told to respond with a list of specific actions taken to correct the violations and prevent their recurrence. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fishman-chemical-north-carolina-llc-609362-07212020?ref=fdaweb.com).

**MMSTabs.com**, (8/3): A recent FDA review of the firm’s Web site determined that it offers for sale unapproved drug products for preventing Covid-19\. The agency cited false and misleading claims such as “From many resources on the ground, we have established a Covid-19 Protocol and have added additional safety measures to protect you from the virus.” Another claim that FDA cited was “Our protocol has been tested in China for the past two months and is been used around the world. Chlorine Dioxide (CLO2) destroys all viruses naturally.” The letter requested that the company take immediate action to cease the sale of such unapproved and unauthorized products. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmstabscom-609461-08032020?ref=fdaweb.com).